CN105142730B - 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂 - Google Patents

环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂 Download PDF

Info

Publication number
CN105142730B
CN105142730B CN201480024011.1A CN201480024011A CN105142730B CN 105142730 B CN105142730 B CN 105142730B CN 201480024011 A CN201480024011 A CN 201480024011A CN 105142730 B CN105142730 B CN 105142730B
Authority
CN
China
Prior art keywords
mannitol
mixture
hcl
cyclobenzaprine hcl
cyclobenzaprine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480024011.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN105142730A (zh
Inventor
M·内布洛尼
P·哥伦布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharma Holdings Ltd
Original Assignee
Tonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105142730(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tonix Pharmaceuticals Inc filed Critical Tonix Pharmaceuticals Inc
Priority to CN201910263541.6A priority Critical patent/CN110152005B/zh
Publication of CN105142730A publication Critical patent/CN105142730A/zh
Application granted granted Critical
Publication of CN105142730B publication Critical patent/CN105142730B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480024011.1A 2013-03-15 2014-03-14 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂 Active CN105142730B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910263541.6A CN110152005B (zh) 2013-03-15 2014-03-14 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361792757P 2013-03-15 2013-03-15
US61/792,757 2013-03-15
PCT/US2014/029872 WO2014145156A2 (en) 2013-03-15 2014-03-14 Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910263541.6A Division CN110152005B (zh) 2013-03-15 2014-03-14 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂

Publications (2)

Publication Number Publication Date
CN105142730A CN105142730A (zh) 2015-12-09
CN105142730B true CN105142730B (zh) 2019-04-16

Family

ID=51538423

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480024011.1A Active CN105142730B (zh) 2013-03-15 2014-03-14 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
CN201910263541.6A Active CN110152005B (zh) 2013-03-15 2014-03-14 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910263541.6A Active CN110152005B (zh) 2013-03-15 2014-03-14 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂

Country Status (27)

Country Link
US (11) US9636408B2 (enExample)
EP (2) EP3650081B1 (enExample)
JP (5) JP6310542B2 (enExample)
CN (2) CN105142730B (enExample)
AU (1) AU2014233277B2 (enExample)
BR (1) BR112015022095B1 (enExample)
CA (2) CA2904812C (enExample)
CY (1) CY1122740T1 (enExample)
DK (2) DK2968992T3 (enExample)
ES (2) ES2769879T3 (enExample)
FI (1) FI3650081T3 (enExample)
HR (2) HRP20200055T1 (enExample)
HU (2) HUE047547T2 (enExample)
IL (1) IL241353B (enExample)
LT (2) LT3650081T (enExample)
MX (2) MX388137B (enExample)
MY (1) MY196014A (enExample)
NZ (2) NZ631152A (enExample)
PL (2) PL2968992T3 (enExample)
PT (2) PT3650081T (enExample)
RS (2) RS60015B1 (enExample)
SA (1) SA515361124B1 (enExample)
SG (2) SG11201507124XA (enExample)
SI (2) SI2968992T1 (enExample)
SM (2) SMT202400324T1 (enExample)
TW (2) TWI661825B (enExample)
WO (1) WO2014145156A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8483821B2 (en) 2009-07-27 2013-07-09 Cardiac Pacemakers, Inc. Blood volume redistribution therapy for heart failure
HUE037281T2 (hu) 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
MX382516B (es) * 2012-06-15 2025-03-13 Tonix Pharmaceuticals Inc Composiciones y metodos para absorcion transmucosa.
NZ631152A (en) 2013-03-15 2017-05-26 Tonix Pharmaceuticals Inc Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
MX383378B (es) 2014-02-05 2025-03-13 Merck Sharp & Dohme Llc Formulación de tableta para compuestos activos de péptido relacionado con el gen de calcitonina.
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US10357465B2 (en) * 2014-09-18 2019-07-23 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride
JP2021505629A (ja) * 2017-12-11 2021-02-18 トニックス ファーマ ホールディングス リミテッド 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2021002012A (es) * 2018-08-20 2021-04-28 Tonix Pharma Holdings Ltd Metodos de tratamiento del trastorno por estres agudo y trastorno por estres postraumatico.
NL2023661B1 (en) * 2019-08-19 2021-04-21 Seranovo Holding B V Pharmaceutical Eutectic Salt Formulation
JP7088153B2 (ja) * 2019-09-19 2022-06-21 カシオ計算機株式会社 Ｃａｐ（周期性脳波活動）検出装置、ｃａｐ（周期性脳波活動）検出方法及びプログラム
WO2021207561A1 (en) 2020-04-08 2021-10-14 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for sexual dysfunction
EP4247370A1 (en) * 2020-11-20 2023-09-27 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for alcohol use disorder
JP2023554692A (ja) 2020-12-07 2023-12-28 トニックス ファーマシューティカルズ ホールディング コーポレイション 線維筋痛症のためのシクロベンザプリン処置
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022170107A2 (en) 2021-02-04 2022-08-11 Tonix Pharmaceuticals Holding Corp. An improved method of assessing clinical response in the treatment of ptsd symptoms
CN113116843A (zh) * 2021-05-11 2021-07-16 福建海西新药创制有限公司 一种含有缬沙坦的药物组合物及其制备方法
AU2022353124A1 (en) 2021-09-27 2024-04-11 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
WO2023059728A1 (en) 2021-10-06 2023-04-13 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
CN120379655A (zh) 2022-06-21 2025-07-25 通尼克斯医药控股公司 (sars)-cov-2感染的急性后后遗症(pasc)的环苯扎林治疗
WO2025160302A1 (en) 2024-01-25 2025-07-31 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for acute stress reaction or acute stress disorder
CN120059783B (zh) * 2025-04-24 2025-07-04 太原理工大学 一种低共熔溶剂循环萃取促进沥青快速氧化的方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
JP2551754B2 (ja) * 1986-04-17 1996-11-06 内橋エステック 株式会社 ペレツト型温度ヒユ−ズ
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
FR2635461B1 (fr) 1988-08-18 1992-01-17 Adir Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1994018954A1 (en) 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of biologics and compositions useful therefor
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE4439858A1 (de) * 1994-11-08 1996-05-09 Merck Patent Gmbh Durch Co-Sprühtrocknung erhältliche Polyol-Zusammensetzung
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
CA2331542A1 (en) 1998-05-14 1999-11-18 Alza Corporation Antidepressant therapy
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
ES2192156B1 (es) 1999-08-13 2005-02-16 Vela Pharmaceuticals, Inc. Composiciones de uso para tratar o prevenir alteraciones del sueño usando dosis muy bajas de ciclobenzaprina.
US6358944B1 (en) 1999-08-13 2002-03-19 Vela Pharmaceuticals, Inc. Methods and compositions for treating generalized anxiety disorder
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001089476A1 (en) 2000-05-19 2001-11-29 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
DK1441708T3 (da) 2001-11-05 2009-07-06 Krele Pharmaceuticals Llc Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
US7105486B2 (en) 2002-02-22 2006-09-12 New River Pharmaceuticals Inc. Abuse-resistant amphetamine compounds
US7659253B2 (en) 2002-02-22 2010-02-09 Shire Llc Abuse-resistant amphetamine prodrugs
MXPA05004381A (es) 2002-10-25 2006-02-10 Collegium Pharmaceutical Inc Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos.
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US20050059656A1 (en) 2003-04-07 2005-03-17 Cornell Research Foundation, Inc. Compositions and methods for protecting against mitochondria component-mediated pathology
KR101170840B1 (ko) 2003-05-29 2012-08-03 샤이어 엘엘씨 남용 방지성 암페타민 화합물
EP1685115A1 (en) 2003-11-03 2006-08-02 Warner-Lambert Company LLC Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
EP1727520A2 (en) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
KR20070030178A (ko) 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI377913B (en) 2005-01-24 2012-12-01 Food Science Co Ltd B Eutectic crystalline sugar alcohol and manufacturing method thereof
US7532935B2 (en) 2005-07-29 2009-05-12 Cyberonics, Inc. Selective neurostimulation for treating mood disorders
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080146672A1 (en) * 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
EP2514417A3 (en) 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
EP2170064A4 (en) 2007-06-22 2010-08-04 Merck Sharp & Dohme 6,5-pyrrolopiperidine tachykinin receptor antagonists
NZ583193A (en) 2007-07-23 2012-05-25 Biotie Therapies Inc Treatment of post-traumatic stress disorder with nepicastat
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
US9254268B2 (en) 2007-09-25 2016-02-09 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
JP5737949B2 (ja) 2008-02-08 2015-06-17 キューピーエス リミテッド ライアビリティ カンパニー 薬物制御送達用の非ポリマー組成物
US9314469B2 (en) 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
JP5380909B2 (ja) 2008-05-30 2014-01-08 株式会社ブリヂストン 金型及び樹脂発泡成形品の成形方法
US20100266682A1 (en) 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US20100247586A1 (en) 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US8871263B2 (en) * 2009-09-24 2014-10-28 Mcneil-Ppc, Inc. Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
HUE037281T2 (hu) 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
WO2012050594A1 (en) 2010-09-01 2012-04-19 Tonix Pharmaceuticals, Inc. Treatment for cocaine addiction
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
ITMI20110558A1 (it) 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
US20130035362A1 (en) 2011-08-04 2013-02-07 Omeros Corporation Stable Anti-inflammatory Solutions for Injection
MX382516B (es) 2012-06-15 2025-03-13 Tonix Pharmaceuticals Inc Composiciones y metodos para absorcion transmucosa.
NZ631152A (en) * 2013-03-15 2017-05-26 Tonix Pharmaceuticals Inc Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US10357465B2 (en) 2014-09-18 2019-07-23 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride
MX2021002012A (es) 2018-08-20 2021-04-28 Tonix Pharma Holdings Ltd Metodos de tratamiento del trastorno por estres agudo y trastorno por estres postraumatico.

Also Published As

Publication number Publication date
PT2968992T (pt) 2020-02-18
EP3650081A1 (en) 2020-05-13
US9636408B2 (en) 2017-05-02
EP2968992A2 (en) 2016-01-20
TW201519889A (zh) 2015-06-01
JP2019196407A (ja) 2019-11-14
SMT202000045T1 (it) 2020-05-08
SG11201507124XA (en) 2015-10-29
PT3650081T (pt) 2024-06-18
US20140336264A1 (en) 2014-11-13
ES2769879T3 (es) 2020-06-29
ES2982441T3 (es) 2024-10-16
LT2968992T (lt) 2020-03-25
IL241353A0 (en) 2015-11-30
BR112015022095B1 (pt) 2021-12-07
CN110152005B (zh) 2023-08-04
SG10201707528WA (en) 2017-10-30
EP2968992A4 (en) 2016-09-07
US11737991B2 (en) 2023-08-29
SI2968992T1 (sl) 2020-04-30
DK3650081T3 (en) 2024-05-21
MX370021B (es) 2019-11-28
HRP20240648T1 (hr) 2024-08-02
DK2968992T3 (da) 2020-02-03
TWI661825B (zh) 2019-06-11
CN105142730A (zh) 2015-12-09
US20210038538A1 (en) 2021-02-11
HRP20200055T1 (hr) 2020-04-03
BR112015022095A8 (pt) 2019-11-26
HK1218727A1 (en) 2017-03-10
CA2904812C (en) 2021-07-20
AU2014233277B2 (en) 2019-04-04
US20250360093A1 (en) 2025-11-27
SMT202400324T1 (it) 2024-11-15
JP2023181495A (ja) 2023-12-21
US20190022030A1 (en) 2019-01-24
EP3650081B1 (en) 2024-02-14
MX2019014200A (es) 2020-01-27
CN110152005A (zh) 2019-08-23
NZ747040A (en) 2020-02-28
JP2021143208A (ja) 2021-09-24
RS65500B1 (sr) 2024-06-28
PL2968992T3 (pl) 2020-06-01
CY1122740T1 (el) 2021-03-12
US9956188B2 (en) 2018-05-01
JP6310542B2 (ja) 2018-04-11
BR112015022095A2 (pt) 2017-07-18
US10322094B2 (en) 2019-06-18
TWI740136B (zh) 2021-09-21
FI3650081T3 (fi) 2024-05-16
RS60015B1 (sr) 2020-04-30
MX388137B (es) 2025-03-19
MY196014A (en) 2023-03-06
WO2014145156A2 (en) 2014-09-18
HUE066883T2 (hu) 2024-09-28
CA3119755A1 (en) 2014-09-18
LT3650081T (lt) 2024-06-10
US20210093585A1 (en) 2021-04-01
US10864175B2 (en) 2020-12-15
SI3650081T1 (sl) 2024-06-28
CA2904812A1 (en) 2014-09-18
EP2968992B1 (en) 2019-12-11
US20170239195A1 (en) 2017-08-24
US20190022031A1 (en) 2019-01-24
TW201936180A (zh) 2019-09-16
CA3119755C (en) 2024-05-28
US20240315988A1 (en) 2024-09-26
MX2015012622A (es) 2016-05-31
PL3650081T3 (pl) 2024-06-24
AU2014233277A1 (en) 2015-10-29
JP2016515528A (ja) 2016-05-30
US11839594B2 (en) 2023-12-12
NZ631152A (en) 2017-05-26
SA515361124B1 (ar) 2018-09-13
US20190282517A1 (en) 2019-09-19
IL241353B (en) 2019-10-31
EP2968992B8 (en) 2020-01-15
US10864176B2 (en) 2020-12-15
US20160030576A1 (en) 2016-02-04
US20180344668A1 (en) 2018-12-06
WO2014145156A3 (en) 2015-01-08
US10117936B2 (en) 2018-11-06
US10736859B2 (en) 2020-08-11
JP2018087231A (ja) 2018-06-07
HUE047547T2 (hu) 2020-04-28

Similar Documents

Publication Publication Date Title
CN105142730B (zh) 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
CN112618494A (zh) 环苯扎林盐酸盐的低共熔混合物配制剂
HK40013124A (en) Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
HK40013124B (zh) 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
HK40030559A (en) Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
HK1218727B (en) Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
HK40047283A (en) Eutectic formulations of cyclobenzaprine hydrochloride
HK40030559B (en) Eutectic formulations of cyclobenzaprine hydrochloride and mannitol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20201127

Address after: Bermuda (UK) Hamilton

Patentee after: TONIX PHARMA HOLDINGS Ltd.

Address before: New York, USA

Patentee before: TONIX PHARMACEUTICALS, Inc.

TR01 Transfer of patent right